Absci

Absci Capital Expenditures

The Capital Expenditures (CapEx) of Absci (ABSI) as of Oct 17, 2026 is -1.11 M USD. In the previous year, Capital Expenditures (CapEx) was -404,000.00 USD — a change of 174.01% (lower).

Capital Expenditures

-1.11 MUSD

YoY

174.01%

Last updated:

Capital Expenditures (CapEx) of Absci is 2025 -1.11 M USD. Capital Expenditures (CapEx) of Absci was 2024 -404,000.00 USD. It decreases by 174.01% lower compared to the previous year.

The Absci Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-1.10 M USD
Jan 1, 2020
-2.18 M USD
Jan 1, 2021
-38.05 M USD
Jan 1, 2022
-16.18 M USD
Jan 1, 2023
-860,000.00 USD
Jan 1, 2024
-404,000.00 USD
Jan 1, 2025
-1.11 M USD
The Absci Capital Expenditures history
YEARCapital ExpendituresYoY
-1.11 MUSD+174.01%
-404,000.00USD-53.02%
-860,000.00USD-94.68%
-16.18 MUSD-57.49%
-38.05 MUSD+1,644.48%
-2.18 MUSD+98.63%
-1.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Capital Expenditures (CapEx) of Absci is -1.11 M USD in 2025.

Capital Expenditures (CapEx) of Absci changed from -404,000.00 USD to -1.11 M USD, representing a 174.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Absci since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Absci historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Absci

All Key Metrics — Absci